Stiff-Person Syndrome

Table of Contents

  1. Overview and History
  2. Pathophysiology: GABAergic Dysfunction
  3. Antibodies and Variants
  4. Clinical Features: Rigidity and Spasms
  5. Autonomic and Psychological Features
  6. Paraneoplastic Stiff-Person Syndrome
  7. Diagnosis
  8. EMG Findings
  9. Treatment: GABA-ergic Drugs
  10. Treatment: Immunotherapy
  11. Prognosis and Living with SPS
  12. Key Research Papers
  13. Featured Videos
  14. Connections

Overview and History

Stiff-Person Syndrome (SPS) was originally described as "stiff-man syndrome" by Moersch and Woltman at the Mayo Clinic in 1956, who documented 14 patients with progressive fluctuating muscular rigidity and spasm (PMID: 13350523). The name was changed to Stiff-Person Syndrome after recognition that the condition affects women at twice the rate of men (F:M ratio approximately 2:1).

SPS is a rare disorder with an estimated prevalence of 1–2 per million people. It is now categorized as an autoimmune CNS disorder affecting spinal cord inhibitory circuits. The disease is characterized by three hallmark features: progressive rigidity primarily affecting the axial muscles, paroxysmal painful muscle spasms triggered by external stimuli, and hyperlumbar lordosis — an exaggerated inward curve of the lower back caused by continuous paraspinal muscle contraction.

SPS is frequently misdiagnosed early in its course as anxiety disorder, Parkinson's disease, multiple sclerosis, fibromyalgia, or conversion (functional neurological) disorder. The mean diagnostic delay is 5–7 years from symptom onset to correct diagnosis. SPS is strongly associated with other autoimmune diseases: type 1 diabetes mellitus (present in 30–40% of SPS patients), autoimmune thyroiditis, vitiligo, and pernicious anemia. In December 2022, singer Celine Dion publicly disclosed her SPS diagnosis, dramatically raising awareness of the condition among the general public.

Back to Table of Contents

Pathophysiology: GABAergic Dysfunction

The central mechanism of SPS involves impairment of GABAergic inhibitory transmission in the spinal cord. GAD65 — glutamic acid decarboxylase, 65 kDa isoform — is the rate-limiting enzyme for GABA synthesis in the central nervous system. Anti-GAD65 autoantibodies found in SPS patients are present at very high titers (typically greater than 2000 U/mL), distinguishing them from the lower-titer anti-GAD65 antibodies seen in type 1 diabetes without SPS.

These antibodies impair GAD65 function, reducing GABA synthesis in spinal interneurons. GABA is the primary inhibitory neurotransmitter in the CNS. In the spinal cord, GABAergic Renshaw cells and Ia inhibitory interneurons continuously modulate alpha-motor neuron firing, preventing excessive muscle contraction. When this GABAergic inhibition is lost, alpha-motor neurons fire tonically — producing continuous muscle contraction and the characteristic stiffness of SPS.

The loss of reciprocal inhibition is equally important: normally, contraction of an agonist muscle is coordinated with inhibition of the opposing antagonist. In SPS, this reciprocal inhibition fails, resulting in simultaneous co-contraction of both agonist and antagonist muscles. This co-contraction can be demonstrated on EMG and is one of the key diagnostic findings.

The pathophysiology of SPS at the spinal cord level closely resembles the effect of tetanus toxin, which cleaves synaptobrevin (a SNARE protein) and blocks GABA and glycine vesicle release from inhibitory interneurons — producing the same result of uncontrolled motor neuron firing and sustained muscle rigidity.

Back to Table of Contents

Antibodies and Variants

Anti-GAD65 antibodies are the most common antibody in SPS, present in 60–80% of patients. Titers above 2000 U/mL are diagnostically significant. Lower titers are commonly found in type 1 diabetes mellitus without SPS and are not specifically associated with neurological disease. Very high titers in the context of the clinical syndrome are strongly supportive of the diagnosis.

Amphiphysin antibodies are present in approximately 5% of SPS cases and are strongly associated with a paraneoplastic etiology. Amphiphysin is a synaptic vesicle protein involved in endocytosis. Amphiphysin-antibody SPS is most commonly associated with breast cancer in women and small cell lung cancer in men. This variant tends to present with more severe disease and may include additional features such as vertical gaze palsy, cerebellar ataxia, and upper motor neuron signs beyond typical SPS.

Glycine receptor (GlyR) antibodies are associated with a more severe condition called progressive encephalomyelitis with rigidity and myoclonus (PERM). This variant involves brainstem structures and presents with hyperekplexia (pathological startle reflex), myoclonus, and autonomic instability in addition to rigidity. GlyR-antibody disease tends to have a more fulminant course than classic GAD65-positive SPS.

GABA-A and GABA-B receptor antibodies are rarely identified in SPS-spectrum disorders. Seronegative SPS — in which no antibodies can be detected — accounts for approximately 20% of cases. In these patients, diagnosis rests on clinical features and EMG findings alone, with response to GABA-ergic therapy providing additional diagnostic support.

Back to Table of Contents

Clinical Features: Rigidity and Spasms

SPS has an insidious onset with gradual worsening over months to years. The rigidity is most prominent in the lumbar paraspinal muscles and abdominal muscles, producing the characteristic "board-like" abdomen — a hardness and firmness of the abdominal wall at rest that is a classic finding on physical examination. Proximal limb muscles are also commonly affected, while the facial and cervical muscles are typically spared in classic SPS.

Hyperlumbar lordosis — an exaggerated lumbar curve visible on standing — results from continuous paraspinal muscle contraction pulling the spine into extension. This postural change may be incorrectly attributed to an orthopedic condition such as spondylosis or disc disease, contributing to diagnostic delay. Rigidity worsens predictably with emotional stress, sudden noise, unexpected touch, and startle.

Paroxysmal spasms are sudden, extremely painful episodes of muscle contraction superimposed on the baseline rigidity. They are reliably triggered by: sudden loud noises (auditory startle), unexpected touch or physical contact, emotional upset or anxiety, and sudden voluntary movement. Spasms last seconds to minutes but are agonizing — many patients describe them as among the most painful experiences of their lives. The force generated during spasms can be powerful enough to cause fractures, particularly of the vertebrae and long bones. Falls from spasm-triggered loss of balance are a major source of injury and disability.

Walking becomes progressively more difficult due to the combination of axial rigidity, limb involvement, and the constant risk of spasm-triggered falls. The gait in established SPS is characteristically stiff, slow, and cautious. Many patients eventually use mobility aids or wheelchairs not from primary motor weakness, but from the mechanical impairment imposed by rigidity and spasm.

Back to Table of Contents

Autonomic and Psychological Features

Agoraphobia — a profound fear of open spaces and public environments — is a striking and diagnostically important feature of SPS. Unlike primary agoraphobia, which is a psychiatric disorder, the agoraphobia in SPS is a rational and understandable consequence of the disease: patients live with the constant awareness that a sudden loud noise, an unexpected touch, or an emotional trigger could produce a violent, painful spasm and cause them to fall in a public place where help may be unavailable. This distinction between rational fear of a genuine physical threat and primary psychiatric agoraphobia is important for appropriate management and validation of patient experience.

Anxiety is both a consequence of living with SPS and a potential trigger for spasms, creating a bidirectional relationship. Depression is very common in SPS, partly reactive to the loss of independence, employment, and social participation, and partly driven by chronic pain. Early in the disease course, the combination of stimulus-sensitive spasms and pronounced anxiety leads many patients to be diagnosed with panic disorder or generalized anxiety disorder before the underlying SPS is identified.

Hyperekplexia — a pathological amplification of the normal startle reflex — is particularly prominent in the GlyR-antibody/PERM variant. Autonomic dysfunction can occur during severe spasm episodes, with episodic diaphoresis (sweating), tachycardia, and blood pressure fluctuation reflecting the massive sympathetic activation produced by the pain and physical stress of the spasm. Social isolation is a nearly universal consequence of advanced SPS, driven by the unpredictability of spasms, the fear of falling, and the exhaustion of managing a high-burden chronic illness.

Back to Table of Contents

Paraneoplastic Stiff-Person Syndrome

Amphiphysin-antibody SPS is almost always paraneoplastic — meaning it arises as an immune reaction to a distant cancer, with the tumor expressing amphiphysin as an aberrant antigen. The most common cancer associations are breast cancer (particularly in women) and small cell lung cancer (particularly in men). Amphiphysin is a synaptic vesicle-recycling protein normally expressed in the CNS, but aberrantly expressed by these tumors, triggering an immune response that cross-reacts with synaptic terminals.

Paraneoplastic SPS typically presents with more rapid onset and more severe neurological involvement than classic GAD65-positive SPS. Additional features beyond the typical SPS triad may include vertical gaze palsy, cerebellar ataxia, peripheral sensory neuropathy, and upper motor neuron signs. The constellation of encephalomyelitis with rigidity in the context of amphiphysin antibodies should trigger an immediate search for an occult malignancy.

The workup includes CT or PET-CT of the thorax, abdomen, and pelvis, and bilateral mammography or breast MRI in women, even in the absence of symptoms attributable to a primary tumor. Treatment of the underlying cancer — through surgery, chemotherapy, or radiation — is the single most important therapeutic intervention for paraneoplastic SPS and may produce neurological improvement that immunotherapy alone cannot achieve.

An important clinical point: anti-GAD65-positive SPS is generally not paraneoplastic. The association between SPS and cancer applies primarily to amphiphysin-antibody cases. Nevertheless, a full paraneoplastic antibody panel and cancer screening should be performed in all new SPS diagnoses, because amphiphysin-positive cases may initially test negative for GAD65, and early cancer detection substantially changes the prognosis.

Back to Table of Contents

Diagnosis

The diagnosis of SPS is based on clinical criteria established by Dalakas (2009), combined with laboratory and electrophysiological findings. The full diagnostic criteria require: (1) stiffness of axial muscles with lumbar and abdominal muscles most prominently affected; (2) simultaneous co-contraction of agonist and antagonist muscles on EMG; (3) episodic painful muscle spasms triggered by external stimuli or emotional stress; (4) hyperlumbar lordosis; (5) continuous motor unit activity (CMUA) on EMG at rest that disappears with diazepam administration or sleep; (6) positive anti-GAD65 antibody at high titer or amphiphysin/GlyR antibody; and (7) clinical response to diazepam.

Laboratory testing should include anti-GAD65 antibodies in serum (and CSF if serum is equivocal or negative), amphiphysin antibodies, glycine receptor antibodies, and a comprehensive paraneoplastic panel. CSF analysis may reveal oligoclonal bands and intrathecal synthesis of anti-GAD65 antibodies, which supports the diagnosis and indicates CNS-specific autoimmunity. Brain and spine MRI is typically normal in classic SPS but is essential to exclude MS, structural lesions, and other mimics.

The differential diagnosis is broad and reflects the typical diagnostic odyssey of SPS patients. Key conditions to exclude include: Parkinson's disease (resting tremor, bradykinesia, dopamine deficiency — responds to levodopa, not diazepam); multiple sclerosis (spasticity, MRI white matter lesions, oligoclonal bands without anti-GAD65); Isaacs syndrome (peripheral nerve hyperexcitability, myokymia, CASPR2/LGI1 antibodies); tetanus (acute onset, wound history, no antibodies); primary dystonia; and anxiety or functional neurological disorder (which is itself a diagnosis of exclusion requiring positive findings). The diazepam response test — IV diazepam abolishing CMUA on EMG — can be both diagnostically and therapeutically informative.

Back to Table of Contents

EMG Findings

Electromyography (EMG) is one of the most important diagnostic tests in SPS, abnormal in approximately 80% of patients. The characteristic finding is continuous motor unit activity (CMUA) at rest in axial muscles — particularly lumbar paraspinals and abdominal muscles. Motor units fire continuously and involuntarily, without any effort by the patient. Importantly, these motor unit potentials are of normal amplitude and morphology, distinguishing CMUA from fasciculations (which are lower amplitude, single fiber) or myotonia (which has a characteristic waxing-and-waning pattern).

The most diagnostically significant feature of CMUA in SPS is its responsiveness to GABA-ergic intervention: CMUA disappears completely with intravenous or oral diazepam administration, with sleep, or under general anesthesia. This pharmacological resolution confirms the GABAergic basis of the abnormal motor unit activity and is considered pathognomonic when present. A bedside diazepam test (carefully monitored IV diazepam while observing EMG) can provide immediate diagnostic confirmation.

During a paroxysmal spasm, EMG shows a dramatic burst of dense, continuous motor unit activity in multiple muscle groups simultaneously, including both agonists and antagonists — the electrophysiological signature of the loss of reciprocal inhibition. Surface EMG (without needle insertion) can be used in clinic to demonstrate co-contraction during voluntary movement or in response to a startle stimulus, providing a non-invasive way to document the abnormal pattern. A normal EMG does not exclude SPS, particularly in early or mild disease, but substantially reduces the likelihood.

Back to Table of Contents

Treatment: GABA-ergic Drugs

Diazepam is the first-line symptomatic treatment for SPS and acts as a positive allosteric modulator of GABA-A receptors, enhancing the effect of residual GABA at inhibitory synapses. The doses required for SPS are typically far higher than those used for anxiety — commonly 20–100 mg per day — and must be titrated carefully to symptom control while monitoring for sedation and respiratory depression. Patients should never stop diazepam abruptly due to the risk of severe withdrawal. The high dose requirement reflects the profound degree of GABAergic deficiency in the spinal cord.

Baclofen, a GABA-B receptor agonist, is used as an adjunct or alternative to benzodiazepines. Oral doses range from 40–120 mg per day. For severe or refractory cases, intrathecal baclofen (ITB) via an implanted pump delivers drug directly to the intrathecal space, allowing much higher local concentrations at spinal cord level with substantially less systemic sedation than oral dosing. ITB is a major surgical intervention but can be highly effective for patients whose rigidity and spasms are not adequately controlled by oral medications.

Clonazepam is an alternative benzodiazepine with a longer half-life that some patients find preferable in terms of durability of effect and tolerability. Tizanidine (an alpha-2 agonist) and sodium valproate (which enhances GABAergic transmission through multiple mechanisms) are occasionally used as adjuncts. Pregabalin and gabapentin have limited evidence in SPS but may provide benefit for the pain component of the disease.

Physical therapy is an essential non-pharmacological adjunct. Hydrotherapy (aquatic physiotherapy) is particularly well tolerated because the buoyancy of water reduces the risk of falls during exercise, allowing patients to maintain muscle conditioning and range of motion that would be unsafe on land. Psychotherapy — particularly CBT addressing the anxiety, agoraphobia, and depression associated with SPS — is an important complement to pharmacological treatment.

Back to Table of Contents

Treatment: Immunotherapy

Intravenous immunoglobulin (IVIG) has the strongest evidence base among immunotherapies for SPS. A landmark randomized controlled trial by Dalakas et al. published in the New England Journal of Medicine in 2001 demonstrated significant improvement in stiffness scores and spasm frequency with IVIG at 2 g/kg administered over 2 days, compared to placebo (PMID: 11794148). IVIG is thought to work through multiple mechanisms including Fc receptor blockade, complement inhibition, and modulation of pathogenic antibody levels. Repeat infusions are typically required every 4–8 weeks for sustained benefit.

Plasma exchange (plasmapheresis) removes circulating anti-GAD65 and other pathogenic antibodies from the bloodstream. Response is often temporary — lasting weeks — because antibody-producing B cells remain active, and antibody levels rebound after treatment. Plasmapheresis is most useful for acute severe exacerbations or as a bridge to longer-term immunotherapy.

Rituximab, an anti-CD20 monoclonal antibody that depletes B cells, is used in refractory cases. Rituximab may produce sustained improvement, particularly in seronegative SPS and in GAD65-positive patients who have not responded adequately to IVIG and steroids. Some patients achieve prolonged remissions after rituximab. Corticosteroids (prednisone) provide modest symptomatic and immunomodulatory benefit but are limited by long-term side effects including worsening of any co-existing type 1 diabetes. Mycophenolate mofetil and azathioprine are used as steroid-sparing maintenance immunosuppressants.

The overarching treatment principle in SPS is to address both the symptoms and the underlying autoimmunity simultaneously. GABA-ergic drugs provide symptomatic relief by compensating for lost inhibitory tone, while immunotherapy addresses the autoimmune process driving antibody production. Most patients with established SPS require both treatment pillars long-term. For paraneoplastic SPS, treatment of the underlying cancer is the foundational intervention, with immunotherapy providing adjunctive benefit.

Back to Table of Contents

Prognosis and Living with SPS

Without treatment, SPS is progressive: rigidity and spasm frequency increase over time, mobility declines, and falls become more frequent and dangerous. With appropriate treatment combining GABA-ergic drugs and immunotherapy, most patients achieve meaningful partial control of symptoms, but complete remission is rare. The disease typically follows a chronic relapsing-remitting or slowly progressive course in GAD65-positive patients.

Quality of life is profoundly affected. Unpredictable painful spasms, constant risk of falls, agoraphobia, social withdrawal, depression, and the high burden of complex medication regimens combine to produce severe functional limitation. The majority of patients with established, severe SPS are unable to maintain employment. SPS is a recognized basis for disability under Social Security criteria in the United States and equivalent programs in other countries.

Prognosis for paraneoplastic (amphiphysin-antibody) SPS depends primarily on the underlying cancer: early detection and successful treatment of the tumor is the single most important prognostic factor. Patients whose cancer is identified and treated early may experience significant neurological improvement. Those with occult or advanced cancer at the time of neurological presentation have a worse prognosis.

Long-term monitoring for all SPS patients should include periodic measurement of anti-GAD65 titers (to gauge immunological activity), annual cancer screening (particularly in amphiphysin-antibody cases), and routine screening for associated autoimmune diseases — specifically HbA1c for type 1 diabetes and thyroid function tests. Spontaneous remissions are very rare in GAD65-positive SPS; occasional near-remissions have been reported in patients with early disease and prompt, aggressive immunotherapy. The rarity of cure reinforces the importance of symptomatic management and psychosocial support as central pillars of long-term care.

Back to Table of Contents

Key Research Papers

  1. Moersch FP & Woltman HW (1956) Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome): report of a case and some observations in 13 other cases. Mayo Clin Proc. PMID: 13350523
  2. Dalakas MC et al. (2001) A controlled study of intravenous immunoglobulin in patients with stiff-person syndrome. N Engl J Med. PMID: 11794148
  3. Solimena M et al. (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. PMID: 3262202
  4. Dalakas MC (2009) Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. PMID: 19581804
  5. Levy LM et al. (1999) Stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med. PMID: 10428735
  6. Butler MH et al. (1993) Amphiphysin: a novel protein associated with synaptic vesicles. J Cell Biol. PMID: 8408189
  7. McKeon A et al. (2012) Glycine receptor autoimmune spectrum with stiff-man syndrome, progressive encephalomyelitis with rigidity and myoclonus, and bilateral limb rigidity. JAMA Neurol. PMID: 22733392
  8. Murinson BB & Guarnaccia JB (2008) Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Arch Neurol. PMID: 18852358
  9. Baizabal-Carvallo JF & Jankovic J (2015) Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. PMID: 24603304
  10. Rakocevic G & Floeter MK (2012) Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Curr Opin Neurol. PMID: 22262060
  11. Martinez-Martinez L et al. (2016) Anti-GAD antibodies are present in a subgroup of patients with young-onset type 2 diabetes. Diabetes Metab. PMID: 26616452
  12. Bhatti AB & Gazali ZA (2015) Recent advances and review on treatment of stiff person syndrome in adults and pediatric patients. Cureus. PMID: 26623183
Back to Table of Contents

Lectures, patient stories, and clinical insights on Stiff-Person Syndrome from neurologists and movement disorder specialists.

Stiff-Person Syndrome

Neurology Education — Stiff-Person Syndrome: diagnosis, mechanisms, and treatment approaches.

Back to Table of Contents

Connections

Back to Table of Contents